Palmitoylethanolamide and polydatin in pediatric irritable bowel syndrome: A multicentric randomized controlled trial
Randomised controlled trialHumansWith polydatin
This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 70 children with irritable bowel syndrome randomised at three Italian centres (34 treatment, 36 placebo). All completed.
- Dose used in the study
- 200 mg of palmitoylethanolamide with 20 mg of polydatin, three times a day
- Duration
- 12 weeks
- What was measured
- Complete remission, defined as a symptom severity score under 75 points at 12 weeks. Frequency and intensity of abdominal pain.
What the authors reported
The trial found:
- Complete remission occurred in 50% of the treatment group versus 22% on placebo (P = 0.015), with particular benefit in the diarrhoea-predominant subtype (P = 0.01).
- Days with abdominal pain fell from 2.89 to 1.32 a week in the treatment group and from 2.89 to 2.52 on placebo.
- No adverse events were recorded.
Limits of this study
The study did not follow children after treatment stopped, so it does not show whether remission lasted. Outcomes were self-reported. The lead author reported that the manufacturer, Epitech, provided the product.
Source
PubMed 38479039 · doi:10.1016/j.nut.2024.112397
Entry checked against the article page at the publisher (ScienceDirect) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.